38 results
Page 2 of 2
8-K
EX-99.1
e6tp7z4v
28 Apr 21
Entry into a Material Definitive Agreement
4:09pm
8-K
EX-99.2
9dg8f6
4 Mar 21
Entry into a Material Definitive Agreement
4:26pm
8-K
EX-99.1
0ho5o1g0jxrf
4 Mar 21
Entry into a Material Definitive Agreement
4:26pm
424B5
4f8k22q55xqv8l4lli
4 Mar 21
Prospectus supplement for primary offering
4:23pm
424B5
meu 2yy92fsi4tbmawx
2 Mar 21
Prospectus supplement for primary offering
4:26pm
8-K
EX-99.1
4mzm7w0
24 Feb 21
Fourth Quarter Revenues of $10.5 Million Represented 47% Sequential Growth Driven by 70% Growth in ProFound AI ® Product Revenue
4:13pm
8-K
EX-99.1
3dc6e
5 Nov 20
Achieved Sequential Revenue Growth of 28% in Third Quarter of 2020, Driven by Detection
4:01pm
8-K
EX-99.1
4j3aec
4 Aug 20
Launched ProFound AI™ Risk Offering After Receiving CE Mark in Europe
4:10pm
8-K
EX-99.1
yyheumeg 5g9wcwj
11 May 20
Recent Equity Offering Strengthens Balance Sheet and Increases Operating Flexibility with focus on Brain Cancer Initiatives
4:24pm
424B5
7achw5ix
24 Apr 20
Prospectus supplement for primary offering
5:11pm
8-K
jr5uhy689i
31 Mar 20
Entry into a Material Definitive Agreement
9:03am
424B5
pah2jzqc2c9pug je
31 Mar 20
Prospectus supplement for primary offering
9:01am
8-K
EX-99.1
34dwgg2n11q7t
28 Feb 20
Strong Q4 2019 revenue growth of 35% driven by a 39% increase in revenue from iCAD’s AI Cancer Detection segment
8:32am